EDP-305 is a farnesoid X receptor (FXR) agonist that selectively activates FXR and is a potential treatment for patients with
nonalcoholic steatohepatitis (NASH) with
liver fibrosis. Results from preclinical studies indicate that
CYP3A4 is the primary
enzyme involved in
EDP-305 metabolism and that
EDP-305 has low potential to inhibit or induce
cytochrome (CYP)
isoenzymes and
drug transporters. Four studies were conducted in healthy volunteers to evaluate the
drug-drug interaction (DDI) potential of
EDP-305 co-administered with drugs known to be substrates for
drug metabolizing
enzymes or transporters, and to assess the effect of inhibitors and inducers of
CYP3A4 on
EDP-305. Results suggest caution when substrates of
CYP3A4 are administered concomitantly with
EDP-305. A potential for increased exposure is apparent when
CYP1A2 substrates with a narrow therapeutic index are administered with
EDP-305. In contrast, substrates of
drug transporters can be administered concomitantly with
EDP-305 with a low potential for interactions. Coadministration of
EDP-305 and a combined OC had no relevant effects on plasma concentrations of the combined OC. Co-administration of
EDP-305 with strong or moderate inhibitors and inducers of
CYP3A4 is not recommended. These results indicate low overall likelihood of interaction of
EDP-305 and other substrates through CYP mediated interactions. The interaction potential of
EDP-305 with
drug transporters was low and of unlikely clinical significance. The
EDP-305 DDI profile allows for convenient administration in patients with NASH and other patient populations with comorbidities, with minimal dose modification of concomitant medications.